

# Metabolic syndrome

Cho L W

## ABSTRACT

**Metabolic syndrome is a clustering of different risk factors that collectively increases the risk of developing cardiovascular disease and type 2 diabetes mellitus. The syndrome itself is associated with various metabolic abnormalities, including insulin resistance, non-alcoholic fatty liver disease, obstructive sleep apnoea, male hypogonadism and polycystic ovary syndrome. This review aims to discuss recent developments related to the syndrome, including the associated metabolic complications and goals for therapeutic strategies.**

**Keywords:** cardiometabolic risk, cardiovascular risk, insulin resistance syndrome, metabolic syndrome

*Singapore Med J 2011; 52(11): 779-785*

## INTRODUCTION

Metabolic syndrome (MetS) identifies patients at increased risk of developing cardiovascular disease (CVD) and type 2 diabetes mellitus. As it is a clustering of different risk factors, and with its pathogenesis not well understood, this has given rise to the development of multiple concurrent definitions. Central obesity and insulin resistance are acknowledged as important causative factors,<sup>(1-3)</sup> together with other associated conditions, including physical inactivity,<sup>(4)</sup> ageing<sup>(5)</sup> and hormonal imbalance<sup>(6,7)</sup> such as polycystic ovary syndrome (PCOS) or testosterone insufficiency.

The concept of clustering of risk factors was first described by Reaven<sup>(8)</sup> in 1988, when the term “insulin resistance syndrome” was conceived. However, as the mechanisms underlying the link to CVD risk factors remain uncertain and insulin resistance is not easily measurable in clinical practice, the more recent consensus, e.g. 2001 National Cholesterol Education Programme (NCEP) Adult Treatment Panel III (ATP III)<sup>(9)</sup> and the 2006 International Diabetes Federation (IDF) criteria,<sup>(10)</sup> favours focusing on other clinical parameters that are easier to measure. It is, therefore, imperative to bear in mind that as the newer criteria did not include insulin resistance as one of its diagnostic criteria, individuals diagnosed as having the syndrome using these criteria may not necessarily be insulin resistant. This is in contrast to the

1999 World Health Organization<sup>(11)</sup> and the 1999 European Group for the Study of Insulin Resistance<sup>(12)</sup> criteria, which emphasised insulin resistance. The IDF consensus, however, takes into account the importance of gender and ethnic differences in predicting early cardiovascular risk and may indeed be a better predictor for risk in women<sup>(13)</sup> and specific ethnic groups, e.g. South Asians (Indians), who appear to be more susceptible to the development of MetS at waist circumferences below that of the NCEP/ATP III cutpoints.<sup>(14)</sup> It is also worth noting that the NCEP/ATP III criteria were revised in 2004, with lowering of threshold for fasting glucose to  $\geq 100$  mg/dL (5.6 mmol/L) in concordance with American Diabetes Association criteria for impaired fasting glucose.<sup>(15)</sup> Hence, in view of the various diagnostic criteria used, care will need to be exercised when interpreting clinical studies related to MetS.

## IMPORTANCE OF METS

MetS continues to be highly prevalent and contributes to a rapidly growing problem globally. About 40% of adults in the US population is estimated to have MetS by the time they reach the age of 60 years.<sup>(5,16)</sup> At least one-fourth of the adult European population may have MetS,<sup>(17-19)</sup> with a similar prevalence in Latin America.<sup>(20)</sup> MetS is also considered an emerging epidemic in developing Asian countries, including Singapore, China, Japan and Korea, with a prevalence of 8%–13% in men and 2%–18% in women, depending on the population and definitions used.<sup>(21-23)</sup>

## PATHOPHYSIOLOGY

There had been several proposed hypotheses for the development of MetS. One such widely quoted hypothesis suggests that adipose tissue dysfunction is the underlying cause, resulting in abnormal metabolism of free fatty acids and the release of adipocytokines that are responsible for the inflammatory changes seen and insulin resistance.<sup>(24-26)</sup> Adipose tissue is in itself an endocrine organ<sup>(27-30)</sup> that is metabolically active, rather than purely an energy storage organ. Adiponectin is secreted exclusively by adipocytes in adipose tissue, and low levels in individuals had consistently predicted the presence of MetS and CVD risk.<sup>(31-35)</sup> In fact, adiponectin can be measured reliably in a clinical setting; its circulating values do not have diurnal fluctuation as much as other

Department of  
Endocrinology,  
Changi General  
Hospital,  
2 Simei Street 3,  
Singapore 529889

Cho LW, MB ChB,  
MRCP, MD  
Consultant and  
Adjunct Assistant  
Professor, Duke-NUS

**Correspondence to:**  
Dr Cho Li Wei  
Tel: (65) 6788 8833  
Fax: (65) 6781 6202  
Email: li\_wei\_cho@  
cgh.com.sg

markers such as insulin, glucose or triglycerides, and only a small amount is required for its measurement, making this a potentially suitable biomarker for MetS.<sup>(36-38)</sup> Resistin<sup>(39-41)</sup> and visfatin<sup>(42-45)</sup> are the other adipocytokines implicated in the pathogenesis of MetS.

An alternative proposed aetiology suggests an underlying state of chronic, low-grade inflammation,<sup>(46-48)</sup> leading to endothelial dysfunction and the release of inflammatory cytokines, which induce insulin resistance in adipose tissue and muscle.<sup>(48,49)</sup> Indeed, insulin-resistant individuals manifest evidence of low-grade inflammation even without an increase in total body fat.<sup>(50)</sup>

## METS AND ASSOCIATED CONDITIONS

### Atherosclerosis

MetS is associated with the clustering of risk factors such as atherogenic dyslipidaemia, elevated blood pressure, endothelial dysfunction<sup>(51)</sup> and arterial stiffness.<sup>(52)</sup> Individuals with these characteristics commonly manifest pro-thrombotic and pro-inflammatory states, with a higher predictive probability of future development of CVD. However, the risk seen is above and beyond the magnitude contributed by the individual components of the syndrome.<sup>(53-63)</sup> The ability of MetS to predict the incidence of CVD may differ, depending on which definition is used. The NCEP/ATP III definition has been associated with a higher predictivity of CVD compared to others,<sup>(64-66)</sup> but the available studies are mainly within the context of Caucasian populations, and may possibly underestimate the risk of CVD in Asian populations.<sup>(67)</sup>

### Type 2 diabetes mellitus

Type 2 diabetes mellitus has been described as a state of heightened cardiovascular morbidity and mortality. CVD is often already present at the time type 2 diabetes mellitus is diagnosed, and patients with diabetes mellitus are twice as likely to develop a cardiovascular event compared to one without the disease. Individuals with diabetes mellitus who have the other co-existing MetS factors have a higher risk for future cardiovascular events,<sup>(68)</sup> and its detection should thus alert clinicians to actively address the risk. In women with gestational diabetes mellitus, the presence of MetS significantly increases their risk of developing type 2 diabetes mellitus,<sup>(69,70)</sup> and therefore, these women should be actively counselled to lose weight through diet and lifestyle modification.

### Insulin resistance

Insulin resistance is an important feature of MetS.<sup>(71)</sup> Although insulin-resistant individuals need not be clinically obese, they commonly have an abnormal fat

distribution that is characterised by predominant upper body obesity (apple shape) rather than lower body obesity (pear shape) and by fat accumulated intra-peritoneally (visceral fat) rather than subcutaneously.<sup>(72)</sup> Upper-body obesity and insulin resistance are associated with a high release of non-esterified fatty acids from adipose tissue,<sup>(72,73)</sup> which results in impaired insulin-mediated hepatic glucose uptake and whole body glucose uptake,<sup>(74)</sup> and possibly, pancreatic beta-cell dysfunction.<sup>(75)</sup>

### Non-alcoholic fatty liver disease

MetS is strongly linked to non-alcoholic fatty liver disease (NAFLD).<sup>(76-78)</sup> The prevalence of NAFLD is around 17%–33% of the general population in Western countries and increases to 57.5%–74.0% in obese individuals.<sup>(79,80)</sup> In the general population of China and Japan, the incidence of NAFLD is lower, at 15% and 14%, respectively.<sup>(81,82)</sup> However, this prevalence has been increasing in the recent years. Hepatic steatosis appears to have a close association with CVD, through the production of risk factors such as very low density lipoprotein, glucose, C-reactive protein, PAI-1 and fibrinogen.<sup>(83-86)</sup> Changes in enzyme gamma-glutamyltransferase and alanine-amino-transferase may also be related to cardiovascular risk.<sup>(87)</sup>

### Obstructive sleep apnoea

Recent evidence suggests that sleep disturbances have strong association with weight gain, insulin resistance, dyslipidaemia, hypertension and CVD.<sup>(88-90)</sup> The association between obstructive sleep apnoea (OSA) with MetS remains significant even when controlled for body mass index,<sup>(91,92)</sup> suggesting that OSA is an independent risk factor for MetS. Elevated free fatty acids<sup>(93)</sup> and left ventricular diastolic dysfunction have also been seen in individuals with OSA.<sup>(94)</sup> Therefore, individuals found to have MetS should be asked (or their partners asked) about snoring and daytime somnolence, especially since the treatment of this condition with nasal continuous positive airway pressure therapy had been shown to successfully improve MetS.<sup>(95-97)</sup>

### Renal disease

MetS is associated with renal adiposity and microvascular proliferation, leading to increased glomerular filtration and activation of oxidative stress and inflammation.<sup>(98)</sup> Individuals with MetS were found to have subclinical renal disease, and conversely those with chronic kidney disease who develop MetS present with a poorer prognosis.<sup>(99,100)</sup> It is therefore expected that treatment of the syndrome would improve the survival of patients with renal disease.

### **Reproductive: polycystic ovary syndrome and male hypogonadism**

PCOS is a common disorder characterised by chronic anovulatory infertility and hyperandrogenism. Clinically, it presents as oligomenorrhoea, hirsutism and acne.<sup>(101)</sup> The prevalence of PCOS is 6%–7% among menstruating women,<sup>(102–105)</sup> but this may differ according to ethnic background; for example, women of South Asian (Indian) origin have a higher prevalence, present at a younger age and have more severe symptoms.<sup>(106,107)</sup> Many women with PCOS are obese and exhibit characteristics of MetS, as suggested by a higher reported incidence of hypertension, dyslipidaemia, visceral obesity, insulin resistance and hyperinsulinaemia.<sup>(108,109)</sup> They also have a higher prevalence of impaired glucose regulation and type 2 diabetes mellitus<sup>(110–113)</sup> as well as a strong association with sleep apnoea.<sup>(114,115)</sup> These women are more likely to fulfill the diagnosis of MetS, with an observed prevalence of 43%–47%.<sup>(6,109,116–118)</sup> Treatment for PCOS traditionally had targeted reproductive abnormalities, but it is also important to understand the potential long-term metabolic implications in order to offer a holistic approach to patient management.

In men, population-based studies have suggested the association of low testosterone with type 2 diabetes mellitus and MetS.<sup>(119–122)</sup> Those with MetS at baseline may also have increased odds of progression to hypogonadism.<sup>(123)</sup> Evidence for the use of testosterone replacement in hypogonadal men with type 2 diabetes mellitus and/or MetS is mixed, with some small studies showing favourable results,<sup>(124,125)</sup> whereas others showed no important cardiovascular effect.<sup>(126,127)</sup> Larger and adequately powered clinical trials are required to assess the benefits and risks of testosterone therapy in these men before any recommendations can be advocated for this purpose.

### **THERAPEUTIC STRATEGIES**

All patients with MetS have a sufficiently high relative risk of CVD to justify for long-term intervention and monitoring in the clinical setting. The emerging epidemic of obesity significantly contributes to the rising prevalence of MetS, and thus burden of healthcare cost for CVD and other related chronic conditions. Intuitively, the first step in curbing this epidemic of MetS and subsequent risk of CVD would be to identify individuals at the early stage of the syndrome, so as to implement preventative measures for further development of the associated cardiometabolic complications. In this respect, there is a role within the public health domain to effectively promote lifestyle changes that are necessary to reduce the burden of the

associated chronic diseases. Another utility for the diagnosis of MetS would be that in view of the “clustering” effect of risk factors, this should prompt clinicians to screen for other associated risks in individuals diagnosed with the syndrome.

The most important therapeutic intervention that has been proven effective in MetS is lifestyle modification through diet and exercise that aims for weight loss. Data from the Diabetes Prevention Programme has demonstrated the powerful effects of diet and exercise in treating patients with impaired glucose tolerance who are at high risk of developing diabetes mellitus. Lifestyle modification through exercise and diet resulted in a net loss of 7% body weight, leading to a 58% reduction in the progression to diabetes mellitus, while the metformin arm in the study showed reduction of only 21%.<sup>(128)</sup>

In the absence of clinical CVD or diabetes mellitus, the Framingham ten-year risk calculator<sup>(129)</sup> for coronary heart disease is a useful tool for estimation of absolute, short-term risk, and should ideally be performed in patients with MetS to guide therapeutic interventions. Individuals who already have diabetes mellitus are in the high-risk category and should be treated according to clinical practice guidelines for diabetes mellitus, and if the risk calculator is used, the UKPDS risk engine<sup>(130)</sup> may be more appropriate for this group of patients. The use of other emerging surrogate markers for CVD, e.g. carotid artery calcification and intima-media thickness, may be considered in certain individuals so as to further quantify their risk status after the ten-year risk score.

The goal for treatment of MetS as a whole is to reduce the lifetime risk for CVD as well as to enable earlier detection and treatment of risk factors. Once an individual has progressed to moderate or high risk of CVD over a ten-year period, drug therapies such as lipid-lowering medications and aspirin should be considered.

### **NEW DIRECTIONS IN THERAPY**

Identification of a syndrome in clinical practice is a stimulus to other areas of medicine. Many publications have arisen, ranging from the epidemiology and prevalence of this syndrome in different populations and the different patterns of clustering in different ethnic groups to metabolic and genetic research on the underlying cause for this syndrome. The importance of the syndrome, as dictated by the “clustering” of the risk factors, is that there may be an underlying unifying pathology that defines the condition. Until the day when we manage to develop drugs that strike the core metabolic susceptibility of this syndrome, we currently continue to recommend medications that target individual risk factors.

## CONCLUSION

The concept of MetS had been and continues to be useful to enhance awareness of risk factor clustering and to promote screening for individuals who present with CVD risk factors. It serves to highlight the risk associated with the increased prevalence of obesity globally and the potential implications in the years to come. Public health effort and healthcare systems have an important role to play in the promotion of weight control and physical activity as a preventative medicine for obesity and MetS.

## REFERENCES

- Anderson PJ, Critchley JA, Chan JC, et al. Factor analysis of the metabolic syndrome: obesity vs insulin resistance as the central abnormality. *Int J Obes Relat Metab Disord* 2001; 25:1782-8.
- Carr DB, Utzschneider KM, Hull RL, et al. Intra-abdominal fat is a major determinant of the National Cholesterol Education Program Adult Treatment Panel III criteria for the metabolic syndrome. *Diabetes* 2004; 53:2087-94.
- Nesto RW. The relation of insulin resistance syndromes to risk of cardiovascular disease. *Rev Cardiovasc Med* 2003; 4 Suppl 6:S11-8.
- Gustat J, Srinivasan SR, Elkasabany A, Berenson GS. Relation of self-rated measures of physical activity to multiple risk factors of insulin resistance syndrome in young adults: the Bogalusa Heart Study. *J Clin Epidemiol* 2002; 55:997-1006.
- Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. *JAMA* 2002; 287:356-9.
- Apridonidze T, Essah PA, Iuorno MJ, Nestler JE. Prevalence and characteristics of the metabolic syndrome in women with polycystic ovary syndrome. *J Clin Endocrinol Metab* 2005; 90:1929-35.
- Saad F, Gooren L. The role of testosterone in the metabolic syndrome: a review. *J Steroid Biochem Mol Biol* 2009; 114:40-3.
- Reaven GM. Banting lecture 1988. Role of insulin resistance in human disease. *Diabetes* 1988; 37:1595-607.
- Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). *JAMA* 2001; 285:2486-97.
- Alberti KG, Zimmet P, Shaw J. Metabolic syndrome--a new worldwide definition. A Consensus Statement from the International Diabetes Federation. *Diabet Med* 2006; 23:469-80.
- Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. *Diabet Med* 1998; 15:539-53.
- Balkau B, Charles MA. Comment on the provisional report from the WHO consultation. European Group for the Study of Insulin Resistance (EGIR). *Diabet Med* 1999; 16:442-3.
- Skilton MR, Moulin P, Sérusclat A, Nony P, Bonnet F. A comparison of the NCEP-ATPIII, IDF and AHA/NHLBI metabolic syndrome definitions with relation to early carotid atherosclerosis in subjects with hypercholesterolemia or at risk of CVD: evidence for sex-specific differences. *Atherosclerosis* 2007; 190:416-22.
- Ajjan R, Carter AM, Somani R, Kain K, Grant PJ. Ethnic differences in cardiovascular risk factors in healthy Caucasian and South Asian individuals with the metabolic syndrome. *J Thromb Haemost* 2007; 5:754-60.
- Grundy SM, Brewer HB Jr, Cleeman JI, et al. Definition of metabolic syndrome: Report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. *Circulation* 2004; 109:433-8.
- Ford ES, Li C, Zhao G. Prevalence and correlates of metabolic syndrome based on a harmonious definition among adults in the US. *J Diabetes* 2010; 2:180-93.
- Martínez MA, Puig JG, Mora M, et al. Metabolic syndrome: prevalence, associated factors, and C-reactive protein: the MADRIC (MADrid Riesgo Cardiovascular) Study. *Metabolism* 2008; 57:1232-40.
- Zanchetti A, Hennig M, Baurecht H, et al. Prevalence and incidence of the metabolic syndrome in the European Lacidipine Study on Atherosclerosis (ELSA) and its relation with carotid intima-media thickness. *J Hypertens* 2007; 25:2463-70.
- Athyros VG, Bouloukos VI, Pehlivanidis AN, et al. The prevalence of the metabolic syndrome in Greece: the MetS-Greece Multicentre Study. *Diabetes Obes Metab* 2005; 7:397-405.
- Escobedo J, Schargrodsky H, Champagne B, et al. Prevalence of the metabolic syndrome in Latin America and its association with sub-clinical carotid atherosclerosis: the CARMELA cross sectional study. *Cardiovasc Diabetol* 2009; 8:52.
- Thomas GN, Ho SY, Janus ED, et al. The US National Cholesterol Education Programme Adult Treatment Panel III (NCEP ATP III) prevalence of the metabolic syndrome in a Chinese population. *Diabetes Res Clin Pract* 2005; 67:251-7.
- Lee J, Ma S, Heng D, et al. Should central obesity be an optional or essential component of the metabolic syndrome? Ischemic heart disease risk in the Singapore Cardiovascular Cohort Study. *Diabetes Care* 2007; 30:343-7.
- Park HS, Kim SM, Lee JS, et al. Prevalence and trends of metabolic syndrome in Korea: Korean National Health and Nutrition Survey 1998-2001. *Diabetes Obes Metab* 2007; 9:50-8.
- Dodson MV, Mir PS, Hausman GJ, et al. Obesity, metabolic syndrome, and adipocytes. *J Lipids* 2011; 2011:721686.
- Ye J. Emerging role of adipose tissue hypoxia in obesity and insulin resistance. *Int J Obes (Lond)* 2009; 33:54-66.
- Lee K, Villena JA, Moon YS, et al. Inhibition of adipogenesis and development of glucose intolerance by soluble preadipocyte factor-1 (Pref-1). *J Clin Invest* 2003; 111:453-61.
- Mohamed-Ali V, Pinkney JH, Coppack SW. Adipose tissue as an endocrine and paracrine organ. *Int J Obes Relat Metab Disord* 1998; 22:1145-58.
- Spiegelman BM, Flier JS. Adipogenesis and obesity: rounding out the big picture. *Cell* 1996; 87:377-89.
- Frühbeck G. The adipose tissue as a source of vasoactive factors. *Curr Med Chem Cardiovasc Hematol Agents* 2004; 2:197-208.
- Rondinone CM. Adipocyte-derived hormones, cytokines, and mediators. *Endocrine* 2006; 29:81-90.
- Bilgili S, Celebiler AC, Dogan A, Karaca B. Inverse relationship between adiponectin and plasminogen activator inhibitor-1 in metabolic syndrome patients. *Endocr Regul* 2008; 42:63-8.
- Alıkaşifoğlu A, Gönc N, Özön ZA, Sen Y, Kandemir N. The relationship between serum adiponectin, tumor necrosis factor-alpha, leptin levels and insulin sensitivity in childhood and adolescent obesity: adiponectin is a marker of metabolic syndrome. *J Clin Res Pediatr Endocrinol* 2009; 1:233-9.
- Bai YM, Chen JY, Yang WS, et al. Adiponectin as a potential biomarker for the metabolic syndrome in Chinese patients taking clozapine for schizophrenia. *J Clin Psychiatry* 2007; 68:1834-9.
- Ahonen TM, Saltevo JT, Kautiainen HJ, Kumpusalo EA, Vanhala MJ. The association of adiponectin and low-grade inflammation with the course of metabolic syndrome. *Nutr Metab Cardiovasc Dis* 2010.
- Okamoto Y. Adiponectin provides cardiovascular protection in metabolic syndrome. *Cardiol Res Pract* 2011; 2011:313179.
- Brooks NL, Moore KS, Clark RD, et al. Do low levels of circulating

- adiponectin represent a biomarker or just another risk factor for the metabolic syndrome? *Diabetes Obes Metab* 2007; 9:246-58.
37. Choi KM, Lee J, Lee KW, et al. Serum adiponectin concentrations predict the developments of type 2 diabetes and the metabolic syndrome in elderly Koreans. *Clin Endocrinol (Oxf)* 2004; 61:75-80.
  38. Tajtáková M, Petrásova D, Petrovicová J, Pytliak M, Semanová Z. Adiponectin as a biomarker of clinical manifestation of metabolic syndrome. *Endocr Regul* 2006; 40:15-9.
  39. Menzaghi C, Coco A, Salvemini L, et al. Heritability of serum resistin and its genetic correlation with insulin resistance-related features in nondiabetic Caucasians. *J Clin Endocrinol Metab* 2006; 91:2792-5.
  40. Mojiminiyi OA, Abdella NA. Associations of resistin with inflammation and insulin resistance in patients with type 2 diabetes mellitus. *Scand J Clin Lab Invest* 2007; 67:215-25.
  41. Steppan CM, Bailey ST, Bhat S, et al. The hormone resistin links obesity to diabetes. *Nature* 2001; 409:307-12.
  42. Fukuhara A, Matsuda M, Nishizawa M, et al. Visfatin: a protein secreted by visceral fat that mimics the effects of insulin. *Science* 2005; 307:426-30.
  43. Araki S, Dobashi K, Kubo K, et al. Plasma visfatin concentration as a surrogate marker for visceral fat accumulation in obese children. *Obesity (Silver Spring)* 2008; 16:384-8.
  44. Filippatos TD, Derdemezis CS, Gazi IF, et al. Increased plasma visfatin levels in subjects with the metabolic syndrome. *Eur J Clin Invest* 2008; 38:71-2.
  45. Sandeep S, Velmurugan K, Deepa R, Mohan V. Serum visfatin in relation to visceral fat, obesity, and type 2 diabetes mellitus in Asian Indians. *Metabolism* 2007; 56:565-70.
  46. Hanley AJ, Festa A, D'Agnostino RB Jr, et al. Metabolic and inflammation variable clusters and prediction of type 2 diabetes: factor analysis using directly measured insulin sensitivity. *Diabetes* 2004; 53:1773-81.
  47. Hu FB, Meigs JB, Li TY, Rifai N, Manson JE. Inflammatory markers and risk of developing type 2 diabetes in women. *Diabetes* 2004; 53:693-700.
  48. Shulman GI. Cellular mechanisms of insulin resistance. *J Clin Invest* 2000; 106:171-6.
  49. Hotamisligil GS. Inflammatory pathways and insulin action. *Int J Obes Relat Metab Disord* 2003; 27 Suppl 3:S53-5.
  50. Chandalia M, Cabo-Chan AV Jr, Devaraj S, et al. Elevated plasma highsensitivity C-reactive protein concentrations in Asian Indians living in the United States. *J Clin Endocrinol Metab* 2003; 88:3773-6.
  51. Alessi MC, Juhan-Vague I. Metabolic syndrome, haemostasis and thrombosis. *Thromb Haemost* 2008; 99:995-1000.
  52. Stehouwer CD, Henry RM, Ferreira I. Arterial stiffness in diabetes and the metabolic syndrome: a pathway to cardiovascular disease. *Diabetologia* 2008; 51:527-39.
  53. Saelly CH, Aczel S, Marte T, et al. The metabolic syndrome, insulin resistance, and cardiovascular risk in diabetic and nondiabetic patients. *J Clin Endocrinol Metab* 2005; 90:5698-703.
  54. Jeppesen J, Hansen TW, Rasmussen S, et al. Insulin resistance, the metabolic syndrome, and risk of incident cardiovascular disease: a population-based study. *J Am Coll Cardiol* 2007; 49:2112-9.
  55. Lakka HM, Laaksonen DE, Lakka TA, et al. The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. *JAMA* 2002; 288:2709-16.
  56. Isomaa B, Almgren P, Tuomi T, et al. Cardiovascular morbidity and mortality associated with the metabolic syndrome. *Diabetes Care* 2001; 24:683-9.
  57. Sattar N, Gaw A, Scherbakova O, et al. Metabolic syndrome with and without C-reactive protein as a predictor of coronary heart disease and diabetes in the West of Scotland Coronary Prevention Study. *Circulation* 2003; 108:414-9.
  58. Girman CJ, Rhodes T, Mercuri M, et al. The metabolic syndrome and risk of major coronary events in the Scandinavian Simvastatin Survival Study (4S) and the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS). *Am J Cardiol* 2004; 93:136-41.
  59. Malik S, Wong ND, Franklin SS, et al. Impact of the metabolic syndrome on mortality from coronary heart disease, cardiovascular disease, and all causes in United States adults. *Circulation* 2004; 110:1245-50.
  60. Olijhoek JK, van der Graaf Y, Banga JD, et al. The metabolic syndrome is associated with advanced vascular damage in patients with coronary heart disease, stroke, peripheral arterial disease or abdominal aortic aneurysm. *Eur Heart J* 2004; 25:342-8.
  61. Gami AS, Witt BJ, Howard DE, et al. Metabolic syndrome and risk of incident cardiovascular events and death: a systematic review and meta-analysis of longitudinal studies. *J Am Coll Cardiol* 2007; 49:403-14.
  62. Wilson PW, D'Agnostino RB, Parise H, Sullivan L, Meigs JB. Metabolic syndrome as a precursor of cardiovascular disease and type 2 diabetes mellitus. *Circulation* 2005; 112:3066-72.
  63. McNeill AM, Rosamond WD, Girman CJ, et al. The metabolic syndrome and 11-year risk of incident cardiovascular disease in the atherosclerosis risk in communities study. *Diabetes Care* 2005; 28:385-90.
  64. Tong PC, Kong AP, So WY, et al. The usefulness of the International Diabetes Federation and the National Cholesterol Education Program's Adult Treatment Panel III definitions of the metabolic syndrome in predicting coronary heart disease in subjects with type 2 diabetes. *Diabetes Care* 2007; 30:1206-11.
  65. Dekker JM, Girman C, Rhodes T, et al. Metabolic syndrome and 10-year cardiovascular disease risk in the Hoorn Study. *Circulation* 2005; 112:666-73.
  66. Timóteo A, Santos R, Lima S, et al. Does the new International Diabetes Federation definition of metabolic syndrome improve prediction of coronary artery disease and carotid intima-media thickening? *Rev Port Cardiol* 2009; 28:173-81.
  67. Tan CE, Ma S, Wai D, Chew SK, Tai ES. Can we apply the National Cholesterol Education Program Adult Treatment Panel definition of the metabolic syndrome to Asians? *Diabetes Care* 2004; 27:1182-6.
  68. Alexander CM, Landsman PB, Teutsch SM, et al. NCEP-defined metabolic syndrome, diabetes, and prevalence of coronary heart disease among NHANES III participants age 50 years and older. *Diabetes* 2003; 52:1210-4.
  69. Verma A, Boney CM, Tucker R, Vohr BR. Insulin resistance syndrome in women with prior history of gestational diabetes mellitus. *J Clin Endocrinol Metab* 2002; 87:3227-35.
  70. Lauenborg J, Mathiesen E, Hansen T, et al. The prevalence of the metabolic syndrome in a danish population of women with previous gestational diabetes mellitus is three-fold higher than in the general population. *J Clin Endocrinol Metab* 2005; 90:4004-10.
  71. Ferrannini E, Haffner SM, Mitchell BD, Stern MP. Hyperinsulinaemia: the key feature of a cardiovascular and metabolic syndrome. *Diabetologia* 1991; 34:416-22.
  72. Jensen MD, Haymond MW, Rizza RA, Cryer PE, Miles JM. Influence of body fat distribution on free fatty acid metabolism in obesity. *J Clin Invest* 1989; 83:1168-73.
  73. Abate N, Chandalia M, Snell PG, Grundy SM. Adipose tissue metabolites and insulin resistance in nondiabetic Asian Indian men. *J Clin Endocrinol Metab* 2004; 89:2750-5.
  74. Iozzo P, Lautamaki R, Geisler F, et al. Non-esterified fatty acids impair insulin-mediated glucose uptake and disposition in the liver. *Diabetologia* 2004; 47:1149-56.
  75. Leung N, Sakaue T, Carpentier A, et al. Prolonged increase of plasma nonesterified fatty acids fully abolishes the stimulatory effect of 24 hours of moderate hyperglycaemia on insulin sensitivity and pancreatic beta-cell function in obese men. *Diabetologia* 2004; 47:204-13.

76. Chang TY, Chen JD. Fatty Liver and Metabolic Syndrome in Nonabdominally Obese Taiwanese Adults. *Asia Pac J Public Health* 2011.
77. Chen SH, He F, Zhou HL, et al. Relationship between nonalcoholic fatty liver disease and metabolic syndrome. *J Dig Dis* 2011; 12:125-30.
78. Roden M. Mechanisms of Disease: hepatic steatosis in type 2 diabetes-- pathogenesis and clinical relevance. *Nat Clin Pract Endocrinol Metab* 2006; 2:335-48.
79. Bedogni G, Miglioli L, Masutti F, et al. Prevalence of and risk factors for nonalcoholic fatty liver disease: the Dionysos nutrition and liver study. *Hepatology* 2005; 42:44-52.
80. Bellentani S, Saccoccio G, Masutti F, et al. Prevalence of and risk factors for hepatic steatosis in Northern Italy. *Ann Intern Med* 2000; 132:112-7.
81. Amarapurkar DN, Hashimoto E, Lesmana LA, et al. How common is nonalcoholic fatty liver disease in the Asia-Pacific region and are there local differences? *J Gastroenterol Hepatol* 2007; 22:788-93.
82. Fan JG, Zhu J, Li XJ, et al. Prevalence of and risk factors for fatty liver in a general population of Shanghai, China. *J Hepatol* 2005; 43:508-14.
83. Kotronen A, Yki-Järvinen H. Fatty liver: a novel component of the metabolic syndrome. *Arterioscler Thromb Vasc Biol* 2008; 28:27-38.
84. Vozarova B, Stefan N, Lindsay RS, et al. High alanine aminotransferase is associated with decreased hepatic insulin sensitivity and predicts the development of type 2 diabetes. *Diabetes* 2002; 51:1889-95.
85. Friis-Liby I, Aldenborg F, Jerlstad P, Rundström K, Björnsson E. High prevalence of metabolic complications in patients with non-alcoholic fatty liver disease. *Scand J Gastroenterol* 2004; 39:864-9.
86. Targher G, Arcaro G. Non-alcoholic fatty liver disease and increased risk of cardiovascular disease. *Atherosclerosis* 2007; 191:235-40.
87. Whitfield JB, Zhu G, Nestler JE, Heath AC, Martin NG. Genetic covariation between serum gamma-glutamyltransferase activity and cardiovascular risk factors. *Clin Chem* 2002; 48:1426-31.
88. Bonsignore MR, Eckel J. ERS Meeting Report. Metabolic aspects of obstructive sleep apnoea syndrome. *Eur Respir Rev* 2009; 18:113-24.
89. Akaoshi T, Uematsu A, Akaoshi T, et al. Obstructive sleep apnoea is associated with risk factors comprising the metabolic syndrome. *Respirology* 2010; 15:1122-6.
90. Alam I, Lewis K, Stephens JW, Baxter JN. Obesity, metabolic syndrome and sleep apnoea: all pro-inflammatory states. *Obes Rev* 2007; 8:119-27.
91. Gruber A, Horwood F, Sithole J, Ali NJ, Idris I. Obstructive sleep apnoea is independently associated with the metabolic syndrome but not insulin resistance state. *Cardiovasc Diabetol* 2006; 5:22.
92. Coughlin SR, Mawdsley L, Mugarza JA, Calverley PM, Wilding JP. Obstructive sleep apnoea is independently associated with an increased prevalence of metabolic syndrome. *Eur Heart J* 2004; 25:735-41.
93. Barceló A, Piérola J, de la Peña M, et al. Free fatty acids and the metabolic syndrome in patients with obstructive sleep apnoea. *Eur Respir J* 2011; 37:1418-23.
94. Baguet JP, Barone-Rochette G, Lévy P, et al. Left ventricular diastolic dysfunction is linked to severity of obstructive sleep apnoea. *Eur Respir J* 2010; 36:1323-9.
95. Chin K, Shimizu K, Nakamura T, et al. Changes in intra-abdominal visceral fat and serum leptin levels in patients with obstructive sleep apnea syndrome following nasal continuous positive airway pressure therapy. *Circulation* 1999; 100:706-12.
96. Ohga E, Tomita T, Wada H, et al. Effects of obstructive sleep apnea on circulating ICAM-1, IL-8, and MCP-1. *J Appl Physiol* 2003; 94:179-84.
97. Ohike Y, Kozaki K, Iijima K, et al. Amelioration of vascular endothelial dysfunction in obstructive sleep apnea syndrome by nasal continuous positive airway pressure--possible involvement of nitric oxide and asymmetric NG, NGdimethylarginine. *Circ J* 2005; 69:221-6.
98. Li Z, Woollard JR, Wang S, et al. Increased glomerular filtration rate in early metabolic syndrome is associated with renal adiposity and microvascular proliferation. *Am J Physiol Renal Physiol* 2011.
99. Martins D, Ani C, Pan D, Ogunyemi O, Norris K. Renal dysfunction, metabolic syndrome and cardiovascular disease mortality. *J Nutr Metab* 2010; 2010: 167162.
100. Ferraro PM, Lupo A, Yabarek T, et al. Metabolic Syndrome, Cardiovascular Disease, and Risk for Chronic Kidney Disease in an Italian Cohort: Analysis of the INCIPE Study. *Metab Syndr Relat Disord* 2011; 9:381-8.
101. Franks S. Polycystic ovary syndrome. *N Engl J Med* 1995; 333:853-61.
102. Azziz R, Woods KS, Reyna R, et al. The prevalence and features of the polycystic ovary syndrome in an unselected population. *J Clin Endocrinol Metab* 2004; 89:2745-9.
103. Asunción M, Calvo RM, San Millán JL, et al. A prospective study of the prevalence of the polycystic ovary syndrome in unselected Caucasian women from Spain. *J Clin Endocrinol Metab* 2000; 85:2434-8.
104. Knochenhauer ES, Key TJ, Kahsar-Miller M, et al. Prevalence of the polycystic ovary syndrome in unselected black and white women of the southeastern United States: a prospective study. *J Clin Endocrinol Metab* 1998; 83:3078-82.
105. Diamanti-Kandarakis E, Kouli CR, Bergiele AT, et al. A survey of the polycystic ovary syndrome in the Greek island of Lesbos: hormonal and metabolic profile. *J Clin Endocrinol Metab* 1999; 84:4006-11.
106. Rodin DA, Bano G, Bland JM, Taylor K, Nussey SS. Polycystic ovaries and associated metabolic abnormalities in Indian subcontinent Asian women. *Clin Endocrinol (Oxf)* 1998; 49:91-9.
107. Wijayaratne CN, Balen AH, Barth JH, Belchetz PE. Clinical manifestations and insulin resistance (IR) in polycystic ovary syndrome (PCOS) among South Asians and Caucasians: is there a difference? *Clin Endocrinol (Oxf)* 2002; 57:343-50.
108. Cussons AJ, Stuckey BG, Watts GF. Metabolic syndrome and cardiometabolic risk in PCOS. *Curr Diab Rep* 2007; 7:66-73.
109. Glueck CJ, Papanna R, Wang P, Goldenberg N, Sieve-Smith L. Incidence and treatment of metabolic syndrome in newly referred women with confirmed polycystic ovarian syndrome. *Metabolism* 2003; 52:908-15.
110. Cibula D, Cífková R, Fanta M, et al. Increased risk of non-insulin dependent diabetes mellitus, arterial hypertension and coronary artery disease in perimenopausal women with a history of the polycystic ovary syndrome. *Hum Reprod* 2000; 15:785-9.
111. Ehrmann DA, Sturis J, Byrne MM, et al. Insulin secretory defects in polycystic ovary syndrome. Relationship to insulin sensitivity and family history of noninsulin-dependent diabetes mellitus. *J Clin Invest* 1995; 96:520-7.
112. Ehrmann DA, Barnes RB, Rosenfield RL, Cavaghan MK, Imperial J. Prevalence of impaired glucose tolerance and diabetes in women with polycystic ovary syndrome. *Diabetes Care* 1999; 22:141-6.
113. Elting MW, Korsen TJ, Bezemer PD, Schoemaker J. Prevalence of diabetes mellitus, hypertension and cardiac complaints in a follow-up study of a Dutch PCOS population. *Hum Reprod* 2001; 16:556-60.
114. Gopal M, Duntley S, Uhles M, Attarian H. The role of obesity in the increased prevalence of obstructive sleep apnea syndrome in patients with polycystic ovarian syndrome. *Sleep Med* 2002; 3:401-4.
115. Fogel RB, Malhotra A, Pillar G, et al. Increased prevalence

- of obstructive sleep apnea syndrome in obese women with polycystic ovary syndrome. *J Clin Endocrinol Metab* 2001; 86:1175-80.
116. Dokras A, Bochner M, Hollinrake E, et al. Screening women with polycystic ovary syndrome for metabolic syndrome. *Obstet Gynecol* 2005; 106:131-7.
117. Ehrmann DA, Liljenquist DR, Kasza K, et al. Prevalence and predictors of the metabolic syndrome in women with polycystic ovary syndrome. *J Clin Endocrinol Metab* 2006; 91:48-53.
118. Essah PA, Nestler JE. Metabolic syndrome in women with polycystic ovary syndrome. *Fertil Steril* 2006; 86 Suppl 1:S18-9.
119. Rodriguez A, Muller DC, Metter EJ, et al. Aging, androgens, and the metabolic syndrome in a longitudinal study of aging. *J Clin Endocrinol Metab* 2007; 92:3568-72.
120. Jones TH, Saad F. The effects of testosterone on risk factors for, and the mediators of, the atherosclerotic process. *Atherosclerosis* 2009; 207:318-27.
121. Zitzmann M. Testosterone deficiency, insulin resistance and the metabolic syndrome. *Nat Rev Endocrinol* 2009; 5:673-81.
122. Traish AM, Guay A, Feeley R, Saad F. The dark side of testosterone deficiency: I. Metabolic syndrome and erectile dysfunction. *J Androl* 2009; 30:10-22.
123. Laaksonen DE, Niskanen L, Punnonen K, et al. The metabolic syndrome and smoking in relation to hypogonadism in middle-aged men: a prospective cohort study. *J Clin Endocrinol Metab* 2005; 90:712-9.
124. Katznelson L, Finkelstein JS, Schoenfeld DA, et al. Increase in bone density and lean body mass during testosterone administration in men with acquired hypogonadism. *J Clin Endocrinol Metab* 1996; 81:4358-65.
125. Jones TH, Arver S, Behre HM, et al. Testosterone replacement in hypogonadal men with type 2 diabetes and/or metabolic syndrome (the TIMES2 study). *Diabetes Care* 2011; 34:828-37.
126. Grossmann M. Low testosterone in men with type 2 diabetes: significance and treatment. *J Clin Endocrinol Metab* 2011; 96:2341-53.
127. Haddad RM, Kennedy CC, Caples SM, et al. Testosterone and cardiovascular risk in men: a systematic review and meta-analysis of randomized placebo-controlled trials. *Mayo Clin Proc* 2007; 82:29-39.
128. Knowler WC, Barrett-Connor E, Fowler SE, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. *N Engl J Med* 2002; 346:393-403.
129. Grundy SM, Pasternak R, Greenland P, Smith S Jr, Fuster V. Assessment of cardiovascular risk by use of multiple-risk-factor assessment equations: a statement for healthcare professionals from the American Heart Association and the American College of Cardiology. *Circulation* 1999; 100:1481-92.
130. Stevens RJ, Kothari V, Adler AI, Stratton IM, United Kingdom Prospective Diabetes study (UKPDS) Group. The UKPDS risk engine: a model for the risk of coronary heart disease in Type II diabetes (UKPDS 56). *Clin Sci (Lond)* 2001; 101:671-9.

## 2011 SMJ Best Research Paper Awards

The Singapore Medical Association will be presenting awards for the Best Research Paper published in the Singapore Medical Journal (SMJ) in 2011. All original research papers that are published in the SMJ during the one year period from January 1, 2011 to December 31, 2011 will be considered for this award.

The following are the judging criteria:

- The paper with the most potential impact on clinical practice
- Most rigorous study design/research methodologies
- Comprehensive data analysis and balanced discussion
- Data interpretation

Distinguished members of the medical profession will be invited to serve on our panel of judges for selecting the winning papers.

The authors of the winning papers selected by our panel of judges will receive cash prizes for the first, second and third places. Prize winners will also receive a commemorative trophy and certificate.

*We thank you for your support of the SMJ. The quality of our journal depends on the quality of your submissions.*

This announcement is sponsored by  **Abbott**  
A Promise for Life